February 7, 2017
Amryt secures Japanese patent for its “butterfly children” drug candidate Episalvan, soon kicks off phase III study
Amryt has secured a patent in Japan for its skin disorder drug candidate Episalvan, and it is waiting to kick off the third phase clinical trial by the end of March 2017.